A new experimental cancer drug called sofetabart mipitecan showed promise in treating advanced ovarian cancer, with about 50.5% of patients experiencing tumor shrinkage in a first-in-human study of 105 patients. According to Gram Research analysis, the drug worked even in patients whose tumors had lower levels of the target protein and in those who had previously tried a similar drug. The most common side effects were nausea, fatigue, and anemia, but the drug avoided serious eye and nerve damage seen with older treatments, suggesting it could offer a better option for heavily treated patients.
Researchers tested a new experimental drug called sofetabart mipitecan (Sofe-M) designed to fight high-grade ovarian cancer by targeting a specific protein called folate receptor alpha. In a first-in-human study of 105 patients with advanced ovarian cancer, about half of the patients saw their tumors shrink or disappear. The drug worked even in patients whose tumors didn’t have high levels of the target protein and in patients who had previously tried a similar drug. The most common side effects were nausea, fatigue, and anemia, but the drug avoided some serious side effects seen with older treatments. These results suggest Sofe-M could offer a new treatment option for patients with this aggressive cancer.
Key Statistics
A 2026 phase 1 trial of 105 patients found that sofetabart mipitecan produced tumor shrinkage in 50.5% of patients with high-grade ovarian cancer, regardless of folate receptor alpha expression level.
In the same 2026 study of 105 ovarian cancer patients, 57.9% of those who had previously tried the similar drug mirvetuximab responded to sofetabart mipitecan, suggesting it could help patients who didn’t benefit from prior treatments.
A 2026 first-in-human trial found that sofetabart mipitecan caused no cases of keratopathy (serious eye damage) and no high-grade nerve damage, compared to the older similar drug which commonly causes these side effects.
The 2026 phase 1 study of sofetabart mipitecan in 105 ovarian cancer patients showed median progression-free survival of 8.1 months, with only 10.5% of patients discontinuing treatment due to side effects.
The Quick Take
- What they studied: Whether a new experimental drug called sofetabart mipitecan could safely treat patients with high-grade ovarian cancer and whether it would shrink their tumors.
- Who participated: 105 patients with advanced high-grade ovarian cancer, with an average age of 63 years. Most patients had already tried multiple other cancer treatments (an average of 5 previous treatments). About 18% had previously tried a similar drug called mirvetuximab, and about half had tumors with lower levels of the target protein.
- Key finding: About 50.5% of all patients saw their tumors shrink or disappear. The drug worked in 58.8% of patients at the 3 mg/kg dose and continued to work in 57.9% of patients who had previously tried a similar drug. Tumors stopped growing for an average of 8.1 months.
- What it means for you: This drug may offer a new treatment option for patients with advanced ovarian cancer, especially those who have already tried other treatments. However, this is early-stage research, and more testing is needed before the drug becomes available. Patients should discuss this research with their oncologist to understand if they might be eligible for future trials.
The Research Details
This was a first-in-human phase 1 clinical trial, which means researchers were testing a completely new drug in humans for the first time. The study included 105 patients with high-grade ovarian cancer who received the drug sofetabart mipitecan at different dose levels (2, 3, 4, or 6 mg/kg) every three weeks. Patients were treated at multiple medical centers, and doctors carefully monitored them for side effects and tumor response. This type of study is designed primarily to test safety and find the best dose, though researchers also look for signs that the drug might work against cancer.
Phase 1 trials are crucial because they’re the first step in testing whether a new drug is safe enough to give to more patients. This study is important because it tests a new approach to treating ovarian cancer that may work better than existing drugs and cause fewer serious side effects. The drug was specifically designed to overcome problems with an older similar drug, so this research could lead to better treatment options for patients with this aggressive cancer.
This study has several strengths: it included a reasonable number of patients (105), followed them for over a year on average, and tested the drug across multiple medical centers. The researchers carefully tracked side effects and measured whether tumors responded to treatment. However, this is still early-stage research with a relatively small group of patients. The study was open-label, meaning both doctors and patients knew they were receiving the experimental drug, which could introduce some bias. Larger studies are needed to confirm these results.
What the Results Show
The drug showed meaningful activity against ovarian cancer tumors. Overall, 50.5% of patients experienced tumor shrinkage or disappearance. When researchers looked at the 3 mg/kg dose specifically (which appears to be the best dose), 58.8% of patients responded. Importantly, the drug worked even in patients whose tumors had lower levels of the target protein (folate receptor alpha), with 44.4% of these patients responding. This is significant because the older similar drug only worked well in patients with high levels of this protein. The drug also worked in patients who had previously tried the older drug, with 57.9% responding, suggesting it could help patients who didn’t benefit from or couldn’t tolerate previous treatments. On average, patients’ tumors stopped growing for 8.1 months, which is a meaningful benefit for patients with this aggressive cancer.
The side effect profile was generally manageable and notably better than the older similar drug. The most common side effects were nausea (occurring in 64.8% of patients), fatigue (56.2%), and anemia, or low red blood cell counts (47.6%). Importantly, the drug did not cause keratopathy, a serious eye condition that occurs with the older drug, and did not cause high-grade nerve damage (neuropathy). At the recommended 3 mg/kg dose, only 35.3% of patients experienced severe side effects (grade 3 or higher), and only 10.5% of patients had to stop treatment because of side effects. These findings suggest the drug has a better safety profile than existing options.
This drug was specifically designed to improve upon mirvetuximab soravtansine-gynx (MIRV), an older drug that targets the same protein. The older drug has limitations: it only works well in patients with high levels of folate receptor alpha, and it causes serious side effects including eye problems and nerve damage. Sofetabart mipitecan appears to overcome these limitations by working in patients with lower levels of the target protein and avoiding the serious eye and nerve side effects. The fact that it worked in patients who had previously tried the older drug suggests it may be a genuinely different approach that could help patients who didn’t respond to or couldn’t tolerate previous treatments.
This is a phase 1 study, which is early-stage research designed primarily to test safety rather than prove effectiveness. The study included only 105 patients, which is relatively small. Patients were treated at multiple centers, which could introduce some variation in how they were treated and monitored. The study was open-label, meaning everyone knew they were receiving the experimental drug, which could bias results. The follow-up period was about 13 months on average, so we don’t know how long the benefits last or what happens to patients over years. Larger, randomized controlled trials are needed to confirm these results and compare the drug to standard treatments. Additionally, this study only included patients with high-grade ovarian cancer, so results may not apply to other cancer types.
The Bottom Line
Based on this early research, sofetabart mipitecan appears to be a promising new treatment option for patients with advanced high-grade ovarian cancer, particularly those who have already tried multiple other treatments. The recommended dose for future testing is 3 mg/kg. However, this is early-stage research, and patients should not expect this drug to be available immediately. Patients with ovarian cancer should discuss this research with their oncologist and ask about opportunities to participate in future clinical trials. This research provides moderate confidence that the drug warrants further testing in larger studies.
This research is most relevant to patients with high-grade ovarian cancer, especially those with advanced disease who have already tried multiple treatments. It may be particularly relevant to patients who tried the older drug mirvetuximab and either didn’t respond or experienced serious side effects. Oncologists treating ovarian cancer should be aware of this research as it may inform future treatment options. Patients should not self-treat or seek out this drug outside of clinical trials, as it is still experimental. This research is less relevant to patients with early-stage ovarian cancer or other cancer types.
In this study, patients who responded to the drug saw tumor shrinkage within weeks to months, though the exact timing wasn’t specified. On average, tumors stopped growing for about 8 months. However, this is early research, and individual results vary widely. Patients should expect that if this drug becomes available, it would take months to see whether it’s working for their specific cancer. The drug is currently in phase 1 testing, so it will likely take several years of additional research before it becomes available to patients outside of clinical trials.
Frequently Asked Questions
Is sofetabart mipitecan available to ovarian cancer patients now?
No, sofetabart mipitecan is still experimental and only available through clinical trials. This 2026 phase 1 study was the first test in humans. Larger trials are underway, and the drug likely won’t be available to the general public for several years. Patients should ask their oncologist about trial eligibility.
How does sofetabart mipitecan work differently from mirvetuximab?
Both drugs target folate receptor alpha on cancer cells, but sofetabart mipitecan was designed to work in patients with lower levels of this protein and to cause fewer serious side effects. The 2026 study showed it avoided keratopathy and high-grade nerve damage that occur with mirvetuximab, while maintaining similar effectiveness.
What are the most common side effects of sofetabart mipitecan?
In the 2026 study of 105 patients, the most common side effects were nausea (64.8%), fatigue (56.2%), and anemia or low red blood cells (47.6%). Most side effects were manageable, and only 10.5% of patients stopped treatment because of side effects.
Can sofetabart mipitecan help patients who already tried mirvetuximab?
Yes, according to the 2026 phase 1 study, 57.9% of patients who had previously tried mirvetuximab responded to sofetabart mipitecan, suggesting it could benefit patients who didn’t respond to or couldn’t tolerate the older drug.
How long does sofetabart mipitecan keep ovarian cancer from growing?
In the 2026 study of 105 patients, tumors stopped growing for an average of 8.1 months. However, this varied among patients, and longer follow-up is needed to understand how long benefits last in individual patients.
Want to Apply This Research?
- If enrolled in a clinical trial for sofetabart mipitecan, track weekly nausea severity (0-10 scale), energy levels, and any new symptoms. Log these alongside imaging scan dates and oncologist visit notes to identify patterns in side effects and treatment response.
- Users interested in this research should set a reminder to discuss clinical trial eligibility with their oncologist at their next appointment. They can use the app to prepare questions about sofetabart mipitecan, document their current treatment history, and track which clinical trials they’ve inquired about or enrolled in.
- For patients enrolled in trials, establish a weekly check-in routine tracking side effect severity, medication adherence, and any new symptoms. Create a calendar reminder for imaging scans and oncology appointments. Use the app to maintain a detailed treatment timeline showing which drugs were tried, when, and how long they worked, which helps oncologists make informed decisions about future treatments.
This article summarizes early-stage research on an experimental drug and is not medical advice. Sofetabart mipitecan is not approved by the FDA and is only available through clinical trials. Patients with ovarian cancer should discuss all treatment options, including clinical trial participation, with their oncologist. This research represents phase 1 findings in a small group of patients; larger studies are needed to confirm safety and effectiveness. Do not attempt to obtain or use this drug outside of authorized clinical trials. Individual results vary, and what works for one patient may not work for another.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.